Physician profile
Daniel Kennedy
NPI 1881658250
$5,644.68
in general payments reported to CMS, 2019-2025
10 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $817 · 2021: $1,879 · 2022: $722 · 2023: $823 · 2024: $526 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,064.48 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $1,434.93 | 2020-2024 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $870.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $360.07 | 2019-2024 | Xarelto |
| Cardiovascular Systems INC. | $334.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $275.65 | 2019-2023 | |
| Integra Lifesciences Corporation | $164.55 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Amarin Pharma, INC. | $125.00 | 2020 | |
| Pfizer INC. | $15.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.